Overall, depletion of STYK1 from cancer cells may diminish persistence mechanisms elicited by EGFR inhibition, such as FGF1 upregulation, and in that way reduce/eliminate the pool of drug tolerant cells in which constitutive, genomic resistance may arise. The gene discussed is EGFR; the disease is cancer.